Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| AroCell's CEO share his views on the company in a video interview | ||
| By: Nasdaq / GlobeNewswire - 13 Feb 2019 | Back to overview list |
|
Today AroCell publishes a short video interview with Michael Brobjer, CEO, and his reflections on his first months at Arocell. The video is available through the link below, AroCell website, and on Financial Hearings web channel. The video is available in Swedish, subtitles will be added shortly. Video: https://tv.streamfabriken.com/2019-02-12-arocell For more information: This information was submitted for publication through the agency of Michael Brobjer, February 13, 2019, at 12:00. About AroCell AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein levels in a blood sample. The TK 210™ ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. Attachment |
||
|
||
 | Back to overview list | |